Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Timing of olanzapine administration for prevention of HEC-induced nausea/vomiting and impact on daytime somnolence
ChiCTR2500100677Phase 3Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of olanzapine in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Incidence of daytime somnolence. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
olanzapine
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on ChiCTR2500100677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100677.